AMGN : Summary for Amgen Inc. - Yahoo Finance

U.S. Markets closed

Amgen Inc. (AMGN)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
174.56+0.55 (+0.32%)
At close: 4:00PM EST

174.56 0.00 (0.00%)
After hours: 5:46PM EST

People also watch
BIIBGILDCELGMRKBMY
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close174.01
Open173.29
Bid173.72 x 500
Ask174.98 x 200
Day's Range172.48 - 174.72
52 Week Range133.64 - 176.85
Volume2,375,353
Avg. Volume3,572,126
Market Cap128.83B
Beta1.67
PE Ratio (TTM)17.05
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield4.60 (2.66%)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • AbbVie Stronger Bet Than Gilead, Amgen — At Least Until 2020: Leerink
    Investor's Business Dailyyesterday

    AbbVie Stronger Bet Than Gilead, Amgen — At Least Until 2020: Leerink

    AbbVie is a stronger stock bet than Gilead Sciences and Amgen, Leerink analyst Geoffrey Porges said Thursday.

  • American City Business Journalsyesterday

    In 'groundbreaking' deal, Harvard Pilgrim negotiates contracts to save on two pricey drugs

    Harvard Pilgrim Health Care has negotiated new payment contracts with two pharmaceutical companies for expensive drugs, progressing a new kind of payment model that could save millions of dollars down the line. If not, the insurer receives a rebate from the pharmaceutical company, which trickles down into more stable premiums for members. “If you think about it, this is considered groundbreaking but it shouldn’t be,” said Michael Sherman, chief medical officer and senior vice president for health services at Harvard Pilgrim.

  • Investopediayesterday

    Amgen Signs Value-Based Deal for Enbrel

    The deal serves a dual purpose: Deliver better value to patients and preserve the drug's market share.